BMS ends 2010 with new pearl on its string, promise for more US approvals
This article was originally published in Scrip
Executive Summary
On the heels of winning an additional six months of US marketing exclusivity protection for its blockbuster heart attack and stroke prevention drug Plavix (clopidogrel bisulfate), Bristol-Myers Squibb delivered a better-than-expected 2010 fourth-quarter earnings report, although sales of Plavix saw only a modest 6% increase from $1.6 billion to $1.7 billion.